All financings
COMPANY TRANSACTIONS

Autonomix Medical, Inc.

AMIXNasdaqMedical - Devices

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES

Deal notes

Not yet verifiedClosing confirmation

Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.

Gross proceeds$4.9M
Offering price$5.75
Discount to prior close-9.1%
Warrant coverage125%
Placement agent / underwriterMaxim Group LLC

Transaction overview

01

Autonomix Medical, Inc. announced a $4.9M warrant exercise / inducement at $5.75 per warrant exercised. Maxim Group LLC acted as warrant inducement agent for the financing.

Financing type
Warrant Exercise / Inducement
Announcement date
Aug 24, 2026
Pricing date
Aug 24, 2026
Closing date
—
Filing date
Aug 26, 2026
Status
Priced
Market cap before announcement
$2.9M
Prior closing price
$5.27
Raise as % of market cap
171%

Market data · FMP

Historical market cap
$2,865,219.95
Market date
Aug 21, 2026
Closing price
$5.27
Latest reported shares outstanding
—
Latest reported float shares
—
Share-data date
—

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.

Financial Modeling Prep ↗

Financing terms

02

Warrant exercise / inducement

Warrants exercised
857,462
Original exercise price
$5.75
Exercise price paid
$5.75
Cash proceeds
$4.9M

Investor warrants

Warrant shares
1,071,826
Cash exercise price
$6.25
Term
Series E-1: 535,913; Series E-2: 535,913. Both five years from issuance; immediately exercisable. E-2 alone has the disclosed Black Scholes redemption right.
Initial exercisability
—
Beneficial ownership limits
The Holder of a New Warrant may not exercise any such warrant to the extent that such exercise would result in the number of shares of common stock beneficially owned by such Holder and its affiliates exceeding 4.99% or 9.99% (at the election of the Holder) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the Holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).

Fees & transaction economics

03
Placement agent / underwriting fee
7%
Agent fee amount
$343,000
Management fee
—
Other offering expenses (estimated)
—
Net proceeds (estimated)
—
Net proceeds as % of gross
—

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

Maxim fee 7% of exercised-warrant cash proceeds; reasonable expenses reimbursable up to $15,000. New E-2 warrants have specified Black Scholes redemption rights; E-1 warrants do not.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

8-K · Autonomix Medical, Inc.SEC filing · Aug 26, 2026
Open source ↗
EX-4.1 · Autonomix Medical, Inc.SEC filing · Aug 26, 2026
Open source ↗
EX-4.2 · Autonomix Medical, Inc.SEC filing · Aug 26, 2026
Open source ↗
EX-10.1 · Autonomix Medical, Inc.SEC filing · Aug 26, 2026
Open source ↗
EX-99.1 · Autonomix Medical, Inc.SEC filing · Aug 26, 2026
Open source ↗
FMP historical market data · AMIXMarket data · Aug 21, 2026
Open source ↗
424B3 · Autonomix Medical, Inc.SEC filing · Sep 16, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.